Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Immunogen Inc (IMGN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,436,235
  • Shares Outstanding, K 132,250
  • Annual Sales, $ 115,450 K
  • Annual Income, $ -96,010 K
  • 36-Month Beta 2.50
  • Price/Sales 13.38
  • Price/Cash Flow N/A
  • Price/Book N/A

Price Performance

See More
Period Period Low Period High Performance
1-Month
7.75 +40.13%
on 02/09/18
12.05 -9.88%
on 02/21/18
+2.31 (+27.02%)
since 01/22/18
3-Month
5.74 +89.20%
on 12/06/17
12.05 -9.88%
on 02/21/18
+5.04 (+86.60%)
since 11/22/17
52-Week
2.43 +346.91%
on 02/23/17
12.05 -9.88%
on 02/21/18
+8.39 (+339.68%)
since 02/22/17

Most Recent Stories

More News
Watch for Immunogen Inc to Potentially Pullback After Gaining 1.20% Yesterday

Immunogen Inc (NASDAQ:IMGN) traded in a range yesterday that spanned from a low of $10.94 to a high of $11.80. Yesterday, the shares gained 1.2%, which took the trading range above the 3-day high of...

IMGN : 11.00 (+1.29%)
Immunogen Inc Has Returned 60.1% Since SmarTrend Recommendation (IMGN)

SmarTrend identified an Uptrend for Immunogen Inc (NASDAQ:IMGN) on December 4th, 2017 at $6.34. In approximately 2 months, Immunogen Inc has returned 60.14% as of today's recent price of $10.15.

IMGN : 11.00 (+1.29%)
Detailed Research: Economic Perspectives on Carbo Ceramics, Consolidated Communications, Catalyst Pharmaceuticals, Office Depot, ImmunoGen, and Cedar Realty Trust -- What Drives Growth in Today's Competitive Landscape

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Carbo Ceramics, Inc. (NYSE:CRR),...

CDR : 4.06 (+1.00%)
CRR : 7.40 (+1.93%)
IMGN : 11.00 (+1.29%)
ODP : 3.09 (+1.98%)
CNSL : 11.34 (-2.74%)
CPRX : 3.15 (unch)
Can ImmunoGen's Key Ovarian Cancer Candidate Drive Growth?

ImmunoGen (IMGN) advances with lead ovarian cancer candidate, mirvetuximab soravtansine. Moreover, combo therapies with the candidate for the indication are underway.

MRK : 54.84 (+0.49%)
IMGN : 11.00 (+1.29%)
RHHBY : 29.8500 (+0.78%)
AMGN : 183.93 (+0.81%)
ImmunoGen (IMGN) Q4 Loss Wider Than Expected, Revenues Grow

ImmunoGen (IMGN) reports wider-than-expected loss in Q4. However, higher license and milestone fees drive substantial revenue rise year over year.

XOMA : 25.35 (-2.50%)
MRK : 54.84 (+0.49%)
IMGN : 11.00 (+1.29%)
RHHBY : 29.8500 (+0.78%)
ImmunoGen (IMGN) Q4 Loss Wider, Revenues Rise Y/Y

ImmunoGen (IMGN) posted wider-than-expected loss in the fourth quarter of 2017. Revenues almost doubled year-over-year.

IMGN : 11.00 (+1.29%)
ImmunoGen Reports Pipeline Progress and 2017 Operating Results

--Mirvetuximab Soravtansine Phase 3 FORWARD I Trial to Complete Enrollment by Mid-Year; FORWARD II Combination Data to be Presented Throughout 2018

IMGN : 11.00 (+1.29%)
Is a Surprise Coming for ImmunoGen (IMGN) This Earnings Season?

ImmunoGen (IMGN) is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat.

IMGN : 11.00 (+1.29%)
ImmunoGen Announces Webcasts of Presentations at Upcoming Conferences

ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the following presentations by...

IMGN : 11.00 (+1.29%)
Is a Beat in the Cards for ImmunoGen (IMGN) in Q4 Earnings?

ImmunoGen's (IMGN) significant progress with lead pipeline candidate, mirvetuximab soravtansine, might drive the stock in Q4.

IMGN : 11.00 (+1.29%)
EXEL : 29.23 (+0.45%)
RHHBY : 29.8500 (+0.78%)
ALKS : 56.55 (-10.51%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Buy with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More

Business Summary

ImmunoGen, Inc. develops pharmaceuticals, primarily for the treatment of cancer. The company's product candidates are called tumor-activated prodrugs and are based on its proprietary immunoconjugate technology platform. Unlike conventional chemotherapeutic agents, tumor-activated prodrugs are intended...

See More

Key Turning Points

2nd Resistance Point 12.55
1st Resistance Point 11.70
Last Price 11.00
1st Support Level 10.35
2nd Support Level 9.85

See More

52-Week High 12.05
Last Price 11.00
Fibonacci 61.8% 8.38
Fibonacci 50% 7.24
Fibonacci 38.2% 6.10
52-Week Low 2.43

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.